Catalent, the Somerset-based provider of drug delivery technologies, is continuing its growth in Europe, acquiring a new facility in Gosselies, Belgium, it announced this week. The company said in a news release that it has acquired Promethera Biosciences’ cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA, and its 32,400-square-foot facility, which will be used to accommodate Catalent’s new commercial-scale plasmid DNA manufacturing. The facility, which has an existing clean room and other laboratory and warehouse space, will be reequipped for Catalent’s needs. It is located on Catalent’s existing campus in Gosselies and represents the third acquisition at the location.
Privacy Overview This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Necessary
Catalent Acquires Additional Facility at its Gosselies, Belgium Campus for Commercial-Scale Plasmid DNA Manufacturing Share Article Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Promethera Biosciences, the world leader in advanced therapy development for severe liver diseases, today announced that Catalent has acquired Promethera’s cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA (HCTS), including its 32,400 square-foot (3,010 square-meter) facility in Gosselies, Belgium. The facility will accommodate Catalent’s new commercial-scale plasmid DNA (pDNA) manufacturing and will provide the opportunity for the immediate growth of Catalent’s pDNA service offering, which was recently acquired from Delphi Genetics to support the growing cell and gene therapy pipeline.
AavantiBio and Catalent Announce Partnership to Support Development and Manufacturing of Gene Therapies for Rare Genetic Diseases Share Article AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a partnership to support the development and manufacturing of AavantiBio’s gene therapies, including its lead program in Friedreich’s Ataxia (FA). Our development team at the University of Maryland BioPark is focused on providing process optimization services to meet our customers’ needs and partnering with them to bring innovative therapies to patients faster
Codagenix Appoints Linda Maldonado as VP, Biologics Chemistry and Manufacturing Controls Ms. Maldonado to Oversee Manufacturing Development of Codagenix s Vaccines as Clinical Trials for COVID-19, RSV and Flu Progress News provided by Share this article Share this article FARMINGDALE, N.Y., April 14, 2021 /PRNewswire/ Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the appointment of biotech industry veteran Linda Maldonado as Vice President, Biologics Chemistry and Manufacturing Controls (CMC). We are pleased to welcome Linda to Codagenix s growing management team in anticipation of multiple significant growth opportunities this year, including the advancement COVI-VAC, our single-dose, intranasal, live-attenuated COVID-19 vaccine, to late-stage clinical trials, said J. Robert Coleman, Ph.D., CEO of Codagenix. Linda has a proven track record with clinical process development, scale-up and technology transfer to GMP production that will be critical to ensuring the productivity, consistency and high quality of all Codagenix vaccines.